Musk: more than 30 people have received the Neuralink implant, next product is BlindSight
Prepared by Sintelligent with the help of SI. Published in SI: . Updated: .
BlindSight has so far only been announced as the next product: the N1 implant remains experimental and Neuralink has no commercial approval.
At the DealBook summit, Elon Musk said that more than 30 people have already received the Neuralink implant. He named Telepathy for people with tetraplegia — controlling a phone, a computer and a robotic arm with thought — as the first product, and BlindSight as the next: a neuroimplant interfaced with the visual cortex, with glasses and a camera that transmits a signal to the device. According to Musk, BlindSight's target group is fully blind people, patients with optic nerve loss and possibly people blind from birth; he called bypassing damage to the neck or spinal cord by linking the motor and sensory cortex so that patients could walk again a promising direction. The N1 implant remains experimental: there is no commercial approval, and trials are under way in the US, Canada, the UK and the UAE. No independent counts of the number of Neuralink implantations were found in verified sources.
Sources 2